Home > Insider Trading > Filing (0000919574-21-004191)

Filing Details

Accession Number:: 0000919574-21-004191
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-06-22 08:58:05
Reporting Period:: 2021-06-16

Accepted Time:: 2021-06-22 08:58:05
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1427570	Reshape Lifesciences Inc.	RSLS	Surgical & Medical Instruments & Apparatus (3841)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1601086	Armistice Capital, Llc	510 Madison Avenue, 7Th Floor New York NY 10022		No	No	Yes	No
1706140	Steven Boyd	C/O Armistice Capital, Llc 510 Madison Avenue, 7Th Floor New York NY 10022		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-06-16	388,045	$6.52	2,021,297	No	4	S	Direct
Common Stock	Disposition	2021-06-16	0	$0.00	2,021,297	No	4	S	Indirect	See Footnote 1
Common Stock	Disposition	2021-06-16	73,591	$7.92	1,947,706	No	4	S	Direct
Common Stock	Disposition	2021-06-16	0	$0.00	1,947,706	No	4	S	Indirect	See Footnote 1
Common Stock	Disposition	2021-06-16	50,040	$8.52	1,897,666	No	4	S	Direct
Common Stock	Disposition	2021-06-16	0	$0.00	1,897,666	No	4	S	Indirect	See Footnote 1
Common Stock	Disposition	2021-06-17	1,024,844	$6.20	872,822	No	4	S	Direct
Common Stock	Disposition	2021-06-17	0	$0.00	872,822	No	4	S	Indirect	See Footnote 1
Common Stock	Disposition	2021-06-17	81,366	$7.13	791,456	No	4	S	Direct
Common Stock	Disposition	2021-06-17	0	$0.00	791,456	No	4	S	Indirect	See Footnote 1
Common Stock	Disposition	2021-06-18	685,583	$5.48	105,873	No	4	S	Direct
Common Stock	Disposition	2021-06-18	0	$0.00	105,873	No	4	S	Indirect	See Footnote 1

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Indirect	See Footnote 1
No	4	S	Direct
No	4	S	Indirect	See Footnote 1
No	4	S	Direct
No	4	S	Indirect	See Footnote 1
No	4	S	Direct
No	4	S	Indirect	See Footnote 1
No	4	S	Direct
No	4	S	Indirect	See Footnote 1
No	4	S	Direct
No	4	S	Indirect	See Footnote 1

Footnotes

The reported securities (the "Shares") of ReShape Lifesciences Inc. (the "Issuer") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital ("Mr. Boyd", and together with Armistice Capital, the "Reporting Persons"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
This constitutes the weighted average purchase price. The prices range from $5.96 to $6.86. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price.
This constitutes the weighted average purchase price. The prices range from $7.30 to $8.06. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price.
This constitutes the weighted average purchase price. The prices range from $8.46 to $8.54. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price.
This constitutes the weighted average purchase price. The prices range from $5.86 to $6.84. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price.
This constitutes the weighted average purchase price. The prices range from $6.91 to $7.51. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price.
This constitutes the weighted average purchase price. The prices range from $5.30 to $5.86. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price.
Additionally, the Reporting Persons no longer have beneficial ownership of 13,333 Shares as a result of the settlement of a transaction made prior to the reporting period. Accordingly, the Reporting Persons have beneficial ownership of 92,540 Shares.